Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels

被引：0
作者：
Katherine A Cappell
Sanatan Shreay
Zhun Cao
Helen V Varker
Carly J Paoli
Matthew Gitlin
机构：
[1] Truven Health Analytics,
[2] Amgen,undefined
[3] Thousand Oaks,undefined
来源：
BMC Nephrology | / 15卷
关键词：
Transfusion; Chronic dialysis; Medicare prospective payment system; End-stage renal disease; Erythropoiesis stimulating agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 94 条
[1]  
Sargent JA(2004)Iron requirements in hemodialysis Blood Purif 22 112-123
[2]  
Acchiardo SR(1998)Erythropoietin for end-stage renal disease N Engl J Med 339 625-627
[3]  
Adamson JW(2006)Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease Am J Kidney Dis 47 S11-S145
[4]  
Eschbach JW(1985)Anemia of end-stage renal disease (ESRD) Kidney Int 28 1-5
[5]  
Eschbach JW(2008)Temporal trends in red blood transfusion among US dialysis patients, 1992–2005 Am J Kidney Dis 52 1115-1121
[6]  
Adamson JW(2006)CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2071-2084
[7]  
Ibrahim HN(2006)CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2085-2098
[8]  
Ishani A(2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med October 361 2019-2032
[9]  
Foley RN(2013)Early trends from the study to evaluate the prospective payment system impact on small dialysis organizations (STEPPS) Am J Kidney Dis 61 947-956
[10]  
Guo H(2013)The DOPPS Practice Monitor for US dialysis care: Trends through December 2011 Am J Kidney Dis 61 342-348
12345678910